| Literature DB >> 27178068 |
Henry Namme Luma1,2, Servais Albert Fiacre Bagnaka Eloumou1,3, Ellis Atemlefeh Fualefeh-Morfaw4, Agnes Malongue1, Elvis Temfack1, Fernando Kemta Lekpa1, Olivier Donfack-Sontsa5, Lucy Ndip4, Ivo Che Ditah6.
Abstract
While gastrointestinal disease is common among HIV infected individuals, the prevalence and distribution of ano-rectal pathology has not been well studied in our setting. The objective of this study therefore was to determine the prevalence and determinants of ano-rectal pathology in HIV infected patients attending the Douala General Hospital HIV treatment centre. A hospital-based cross-sectional study was undertaken. We collected socio-demographic, clinical and laboratory data using a structured questionnaire and patients' files. Each study participant had a full physical and ano-rectal examination. We further studied factors associated with having at least one ano-rectal lesion by logistic regression reporting odds ratios (ORs) and their 95% confidence intervals (CI). We included 390 HIV infected patients. The mean age was 41 (SD: 8) years and 48% were men. Median duration since HIV diagnosis was 3 (interquartile range: 2-5) years and median CD4 cell count was 411 (interquartile range: 234-601) cells/mm3. Prevalence of ano-rectal pathology was 22.8% (95% CI: 18.7-27.3). Hemorrhoids and proctitis were most common lesions found; each in 10% of patients. From multivariate logistic regression, factors associated with ano-rectal pathology were CD4 < 350 cells/ml (OR: 2.1, 95% CI: 1.1-4.2), not on highly active antiretroviral therapy (OR: 2.2, 95% CI: 1.1-4.6), inpatient (OR: 2.3, 95% CI: 1.2-4.3), ano-rectal intercourse (OR: 5.0, 95% CI: 1.7-15.1), and more than one sexual partner (OR: 2.4, 95% CI: 1.3-4.2). Ano-rectal pathology is common amongst HIV infected patients. Care givers should actively investigate and treat them as this will improve the quality of life of people living with HIV/AIDS.Entities:
Keywords: Anorectal pathology; CD4 cell counts; HIV; anorectal intercourse; highly active antiretroviral therapy
Mesh:
Year: 2016 PMID: 27178068 DOI: 10.1177/0956462416650817
Source DB: PubMed Journal: Int J STD AIDS ISSN: 0956-4624 Impact factor: 1.359